Reducing effectively toxic side effects is a challenging subject in drug development. The reported herein cocrystallization of pyrazinamide with quercetin has complementary advantages, enhancing the in vitro/vivo performance of quercetin and taming the pharmacokinetic synergy of quercetin and pyrazinamide, almost removing pyrazinamide induced hepatotoxicity. The findings stimulate the application of active pharmaceutical ingredient–nutraceutical cocrystallization to solve the toxicity issue of drugs.

中文翻译：

---

槲皮素通过互补优势共结晶策略对吡嗪酰胺诱导的肝毒性的保护作用

减少有效的毒副作用是药物开发中具有挑战性的课题。本文报道的吡嗪酰胺与槲皮素的共结晶具有互补的优势，增强了槲皮素的体外/体内性能，并抑制了槲皮素和吡嗪酰胺的药代动力学协同作用，几乎消除了吡嗪酰胺引起的肝毒性。这些发现刺激了药物活性成分-营养共结晶的应用，以解决药物的毒性问题。